StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
LNTHVery BullishM&Anews
High materiality9/10

Curium to buy Lantheus for up to $114.50 per share in cash and CVRs

Aug 3, 2026, 7:33 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Significant per-share cash premium and CVR upside create immediate value for LNTH holders, with a clear path to higher valuations if milestones are met; however, execution risk remains due to regulatory and shareholder approvals and CVR uncertainty.

AI summary

What happened, with direct paths to the underlying reporting

Curium will acquire Lantheus for $102.50 per share in cash plus up to $12 per share in contingent value rights (CVRs), valuing the deal at up to $8 billion. The purchase premium is substantial versus multiple VWAPs, while CVRs introduce milestone-based upside through 2030. The combined company would span diagnostics and radioligand therapy across 70+ countries, with closing anticipated in the first half of 2027, pending approvals.

  • Curium US to acquire Lantheus for up to $114.50 per LNTH share in cash and CVRs.
  • Premium to 60-day VWAP: 38%; to 30-day VWAP: 29%; ~21% to May 21, 2026 close.
  • Near-term value: $102.50 cash at closing plus up to $12 CVRs through 2030.
  • Combined group would operate in 70+ countries, expanding theranostics across diagnostics and therapeutics.
  • Closing expected in 1H 2027, subject to shareholder and regulatory approvals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event